[go: up one dir, main page]

WO2020262104A1 - Composition de résine et modèle de tissu tubulaire de lésion - Google Patents

Composition de résine et modèle de tissu tubulaire de lésion Download PDF

Info

Publication number
WO2020262104A1
WO2020262104A1 PCT/JP2020/023545 JP2020023545W WO2020262104A1 WO 2020262104 A1 WO2020262104 A1 WO 2020262104A1 JP 2020023545 W JP2020023545 W JP 2020023545W WO 2020262104 A1 WO2020262104 A1 WO 2020262104A1
Authority
WO
WIPO (PCT)
Prior art keywords
lesion
resin composition
tubular tissue
component
mass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2020/023545
Other languages
English (en)
Japanese (ja)
Inventor
彰 見山
睦 松本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denka Co Ltd
Original Assignee
Denka Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denka Co Ltd filed Critical Denka Co Ltd
Priority to DE112020003114.4T priority Critical patent/DE112020003114T5/de
Priority to JP2021528254A priority patent/JP7482867B2/ja
Publication of WO2020262104A1 publication Critical patent/WO2020262104A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L53/00—Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers
    • C08L53/02—Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers of vinyl-aromatic monomers and conjugated dienes
    • C08L53/025—Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers of vinyl-aromatic monomers and conjugated dienes modified
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B23/00—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes
    • G09B23/28—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes for medicine
    • G09B23/30—Anatomical models
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K3/00—Use of inorganic substances as compounding ingredients
    • C08K3/18—Oxygen-containing compounds, e.g. metal carbonyls
    • C08K3/24—Acids; Salts thereof
    • C08K3/26—Carbonates; Bicarbonates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L91/00—Compositions of oils, fats or waxes; Compositions of derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K3/00—Use of inorganic substances as compounding ingredients
    • C08K3/18—Oxygen-containing compounds, e.g. metal carbonyls
    • C08K3/24—Acids; Salts thereof
    • C08K3/26—Carbonates; Bicarbonates
    • C08K2003/265—Calcium, strontium or barium carbonate

Definitions

  • the present invention relates to a resin composition and a lesion tubular tissue model using the resin composition.
  • Patent Document 1 proposes an artificial blood vessel containing a block copolymer composed of a polymer block mainly composed of styrene and a polymer block mainly composed of a conjugated diene compound as a fiber reinforced resin.
  • Patent Document 2 proposes a resin composition containing a hydrogenated block copolymer having a predetermined MFR, an oil, and a polyolefin-based resin having a predetermined specific surface area in a predetermined amount as a resin composition used for a tubular structure. Has been done.
  • the artificial tubular tissue is used as a medical simulator for acquiring skills, and it is required that the physical properties are similar to the tubular tissue of animals including humans.
  • a calcified portion may be formed inside the tubular tissue due to a lesion, and the physical properties of the lesion portion may change.
  • An object of the present invention is to provide a resin composition that can be used in a lesion tubular tissue model having physical properties similar to those of a lesion in a tubular tissue of an animal including humans.
  • the present inventor has proceeded with research and found that by adding an inorganic filler to a hydrogenated block copolymer, the physical properties are similar to those of a lesion in a tubular tissue, and have completed the present invention.
  • the present invention relates to the following.
  • [1] A resin composition containing 100 parts by mass of the component (A) hydrogenated block copolymer and 100 to 5900 parts by mass of the component (B) inorganic filler.
  • [2] The method according to [1], wherein the MFR (measured at a temperature of 230 ° C. and a load of 2.16 kg) of the component (A) hydrogenated block copolymer is 0.01 g / 10 minutes or more and 1 g / 10 minutes or less.
  • Resin composition [3]
  • the resin composition according to [1] or [2] which contains 400 to 5000 parts by mass of the component (B) inorganic filler with respect to 100 parts by mass of the component (A) hydrogenated block copolymer.
  • the resin composition according to the first embodiment of the present invention contains 100 parts by mass of component (A) hydrogenated block copolymer and 100 to 5900 parts by mass of component (B) inorganic filler. This makes it possible to obtain a lesion tubular tissue model having physical properties similar to the lesion portion of the tubular tissue of animals including humans.
  • the hydrogenated block copolymer of the component (A) is an aromatic vinyl-conjugated diene block copolymer composed of a block polymerization unit (X) derived from aromatic vinyl and a block polymerization unit (Y) derived from conjugated diene. It is preferable to contain at least one hydrogenated product (hydrogenated product or hydride).
  • the form of the aromatic vinyl-conjugated diene block copolymer having such a structure is represented by, for example, X (YX) n or (XY) n [n is an integer of 1 or more].
  • X (YX) n particularly the one in the form of XYX is preferable.
  • XYX is selected from the group consisting of polystyrene-polybutadiene-polystyrene block copolymer, polystyrene-polyisoprene-polystyrene block copolymer, and polystyrene-polyisoprene butadiene-polystyrene block copolymer.
  • One or more copolymers to be produced are preferable.
  • the aromatic vinyl block unit (X) which is a hard segment, exists as a bridging point of the conjugated diene rubber block unit (Y) and is a pseudo-crosslink (domain). Is forming.
  • the conjugated diene rubber block unit (Y) existing between the aromatic vinyl block units (X) is a soft segment and has rubber elasticity.
  • Aromatic vinyl blocks examples include styrene, ⁇ -methylstyrene, 3-methylstyrene, p-methylstyrene, 4-propylstyrene, 4-dodecylstyrene, 4-cyclohexylstyrene, and the like. Examples thereof include 2-ethyl-4-benzylstyrene, 4- (phenylbutyl) styrene, 1-vinylnaphthalene and 2-vinylnaphthalene. Of these, styrene is preferred.
  • Examples of the conjugated diene forming the conjugated diene block polymerization unit (Y) include butadiene, isoprene, pentadiene, 2,3-dimethylbutadiene, and a combination thereof.
  • one or more conjugated diene selected from the group consisting of butadiene, isoprene, and a combination of butadiene and isoprene (copolymerization of butadiene-isoprene) is preferable.
  • One or more of these conjugated dienes can be used in combination.
  • the conjugated diene block polymerization unit (Y) composed of the butadiene-isoprene copolymer unit may be any of a random copolymerization unit of butadiene and isoprene, a block copolymerization unit, and a tapered copolymerization unit.
  • the content of the aromatic vinyl block polymerization unit (X) is preferably 5% by mass or more and 50% by mass or less, and 20% by mass or more and 40% by mass or less. More preferably: The content of the aromatic vinyl unit can be measured by a conventional method such as infrared spectroscopy or NMR spectroscopy.
  • the aromatic vinyl-conjugated diene block copolymer as described above can be produced by various methods.
  • the production method includes (1) a method of sequentially polymerizing an aromatic vinyl and then a conjugated diene using an alkyllithium compound such as n-butyllithium as an initiator, and (2) polymerizing an aromatic vinyl and then a conjugated diene.
  • an alkyllithium compound such as n-butyllithium as an initiator
  • polymerizing an aromatic vinyl and then a conjugated diene can be mentioned, such as a method of coupling the above with a coupling agent, (3) a method of sequentially polymerizing a conjugated diene and then an aromatic vinyl using a lithium compound as an initiator.
  • the hydrogenated block copolymer is a product (hydrogenated or hydride) obtained by hydrogenating the above aromatic vinyl-conjugated diene block copolymer by a known method, and the preferable hydrogenation rate is 90 mol%. That is all.
  • This hydrogenation rate is a value when the total amount of carbon-carbon double bonds in the conjugated diene block polymerization unit (Y) is 100 mol%. “Hydrogenation rate is 90 mol% or more” means that 90 mol% or more of carbon-carbon double bonds are hydrogenated.
  • hydrogenated block copolymers examples include polystyrene-poly (ethylene / propylene) block (SEP), polystyrene-poly (ethylene / propylene) block-polystyrene (SEPS), and polystyrene-poly (ethylene / butylene) block-.
  • SEP polystyrene-poly (ethylene / propylene) block
  • SEPS polystyrene-poly (ethylene / propylene) block-polystyrene
  • SEBS polystyrene-poly (ethylene-ethylene / propylene) block-polystyrene
  • SEEPS polystyrene-poly (ethylene-ethylene / propylene) block-polystyrene
  • SEEPS is contained as the component (C).
  • the melt flow rate (MFR (temperature 230 ° C., load 2.16 kg)) of the component (A) hydrogenated block copolymer is preferably 0.01 g / 10 minutes or more and 1 g / 10 minutes or less, more preferably. Is 0.05 g / 10 minutes or more and less than 0.1 g / 10 minutes.
  • the MFR (temperature 230 ° C., load 2.16 kg) means an MFR measured under the conditions of a temperature 230 ° C. and a load 2.16 kg according to JIS K7210.
  • the hydrogenation rate is measured by a known method such as nuclear magnetic resonance spectrum analysis (NMR).
  • the shape of the component (A) hydrogenated block copolymer is preferably powder or amorphous (clam) from the viewpoint of oil absorption work before kneading.
  • Component (B) Inorganic filler examples include calcium carbonate, talc, clay (clay), calcium silicate, magnesium carbonate, magnesium hydroxide, mica, barium sulfate, titanium oxide, aluminum hydroxide, silica, alumina, carbon black and the like. Be done. Among these, one or more selected from the group consisting of calcium carbonate, silica, alumina, talc, and clay is preferable, and calcium carbonate is more preferable.
  • composition of the resin composition 100 parts by mass or more of the component (A) hydrogenated block copolymer, 100 parts by mass or more and 5900 parts by mass or less of the component (B) inorganic filler, and more preferably 400 parts by mass or more and 5000 parts by mass of the inorganic filler.
  • the component (C) oil may be further contained.
  • the component (C) oil is most preferably paraffin-based process oil, naphthen-based process oil, mineral oil-based oil such as aromatic process oil or liquid paraffin, silicon oil, castor oil, flaxseed oil, olefin-based wax, and the like.
  • mineral oil-based oil such as aromatic process oil or liquid paraffin
  • silicon oil castor oil
  • flaxseed oil olefin-based wax
  • examples include mineral wax.
  • paraffin-based and / or naphthenic-based process oils are preferred.
  • the process oil include Diana process oil series (manufactured by Idemitsu Kosan Co., Ltd.) and JOMO process P (manufactured by Japan Energy Co., Ltd.).
  • various ester-based plasticizers such as phthalic acid, trimellitic acid, pyromellitic acid, adipic acid, and citric acid can also be used. These plasticizers may be used alone or in combination of two or more.
  • the component (C) oil is previously absorbed by the component (A) hydrogenated block copolymer in advance in terms of workability.
  • the shape of the hydrogenated block copolymer of the component (A) is preferably the powder or amorphous (clam) shape that easily absorbs oil.
  • the component (C) oil preferably has a kinematic viscosity at 37.8 ° C. or 40 ° C. of 0.1 to 1000 m 2 / s, more preferably 0.1 to 500 m 2 / s, and 0.1. It is more preferably ⁇ 100 m 2 / s.
  • a resin composition can be obtained that gives a biological model having softness and physical properties similar to human blood vessels and / or skin.
  • the measurement of kinematic viscosity can be obtained by measuring at a test temperature of 37.8 ° C. or 40 ° C. using a Canon Fenceke viscometer according to “5. Kinematic viscosity test method” of JIS K 2283: 2000.
  • the component (A) hydrogenated block copolymer is 100 parts by mass and the component (C) oil is 3 parts by mass or more and 1500 parts by mass or less, more preferably 5 parts by mass or more and 1200 parts by mass. It is preferably contained in an amount of 8 parts by mass or more, more preferably 500 parts by mass or less.
  • a lubricant may be contained.
  • the lubricant include ionic surfactants, nonionic (nonionic) surfactants, hydrocarbon-based lubricants, fatty acid-based lubricants, aliphatic amide-based lubricants, metal soap-based lubricants, ester-based lubricants and the like.
  • an anionic surfactant As the ionic surfactant, an anionic surfactant, a cationic surfactant, and an amphoteric surfactant can be used.
  • the anionic surfactant include fatty acid sodium, monoalkyl sulfate, alkyl polyoxyethylene sulfate, alkylbenzene sulfonate, monoalkyl phosphate and the like.
  • Examples of commercially available products include the trade name "Electro Stripper PC" manufactured by Kao Corporation.
  • Examples of the cationic surfactant include an alkyltrimethylammonium salt, a dialkyldimethylammonium salt, an alkylbenzyldimethylammonium salt and the like.
  • amphoteric surfactant examples include alkyldimethylamine oxide and alkylcarboxybetaine.
  • nonionic surfactant include polyoxyethylene alkyl ether, fatty acid sorbitan ester, alkyl polyglucoside, fatty acid diethanolamide, alkyl monoglyceryl ether, and the like.
  • trade name "Kao Corporation""Electro stripper EA” and the like can be mentioned.
  • hydrocarbon-based lubricant examples include paraffin wax, synthetic polyethylene wax, octyl alcohol and the like.
  • fatty acid-based lubricant examples include stearic acid and stearyl alcohol.
  • aliphatic amide lubricant examples include fatty acid amides such as stearic acid amide, oleic acid amide and erucic acid amide; and alkylene fatty acid amides such as methylene bisstearic acid amide and ethylene bisstearic acid amide.
  • metal soap-based lubricant examples include a metal stearic acid salt and the like.
  • ester-based lubricant examples include fatty acid esters of alcohols, stearic acid monoglycerides, stearyl stearate, and hydrogenated oils.
  • lubricant one or more selected from the above-mentioned lubricants can be used.
  • lubricants selected from the group consisting of ionic surfactants and nonionic surfactants in that they have softness and physical properties more similar to those of human blood vessels and / or skin.
  • nonionic surfactants it is more preferable to contain one or more selected from nonionic surfactants.
  • the resin composition of the present embodiment preferably contains a lubricant of 0.1 part by mass or more and 150 parts by mass or less with respect to 100 parts by mass of the component (A) hydrogenated block copolymer, and more preferably 0. It is preferably contained in an amount of 1 part by mass or more and 100 parts by mass or less, more preferably 0.1 part by mass or more and 50 parts by mass or less.
  • the resin composition is, if necessary, a rubber, a plasticizer, a stabilizer, an antistatic agent, a light resistance improver, an ultraviolet absorber, a softener, a lubricant, a processing aid, and a colorant.
  • Antistatic agent, antifogging agent, antiblocking agent, crystal nucleating agent, foaming agent and the like may be contained.
  • the resin composition in the present embodiment may contain other resins or elastomers, if necessary.
  • the other resin or elastomer is not particularly limited, but for example, a polyolefin such as polyethylene, polypropylene, an ethylene-propylene copolymer, an ethylene-vinyl acetate copolymer (EVA), or a styrene-butadiene copolymer.
  • Styrene-isoprene copolymer Styrene-isoprene copolymer, styrene-butadiene-isoprene copolymer, styrene-ethylene-butadiene-styrene copolymer (SEBS), styrene-ethylene-propylene-styrene copolymer (SEPS) and other styrene-based thermoplastics Fibrous fillers such as elastomers, acrylonitrile-butadiene-styrene copolymers (ABS resin), acrylic nitrile-styrene copolymers (AS resin), polystyrenes, polyvinyl chlorides, and polyvinylidene chlorides can be mentioned.
  • ABS resin acrylonitrile-butadiene-styrene copolymers
  • AS resin acrylic nitrile-styrene copolymers
  • polystyrenes polyvin
  • the content thereof is preferably 0.01 parts by mass or more and 500 parts by mass or less with respect to 100 parts by mass of the component (A) hydrogenated block copolymer.
  • the resin composition is preferably thermoplastic in terms of manufacturing cost and physical characteristic balance.
  • the A hardness of the resin composition is not particularly limited depending on the lesion tubular tissue model to be produced, but is preferably 1 to 100, more preferably 1 to 80, and even more preferably 1 to 60.
  • the A hardness of the resin composition is preferably 10 to 100, more preferably 40 to 100, further preferably 60 to 100, and most preferably 80 to 100.
  • the A hardness of the resin can be measured according to the durometer hardness test method of JIS K6253-1997.
  • the method for producing the resin composition is not particularly limited, and a known suitable blending method can be used.
  • melt-kneading can be performed with a single-screw or twin-screw screw extruder, a Banbury type mixer, a plast mill, a conider, a heating roll, or the like.
  • each raw material may be uniformly mixed with a Henschel mixer, a ribbon blender, a super mixer, a tumbler, or the like.
  • the melt-kneading temperature is not particularly limited, but is generally 50 to 300 ° C, preferably 70 to 250 ° C.
  • the lesion tubular tissue model of the present embodiment is formed by arranging a pseudo-lesion portion formed from the above resin composition inside the artificial tubular tissue.
  • the artificial tubular tissue preferably has a hollow elongated structure.
  • the inner diameter of the artificial tubular tissue is not particularly limited depending on the type of tubular tissue to be produced, but is preferably 0.1 mm to 30 mm, more preferably 0.5 mm to 20 mm, still more preferably 1 mm to 10 mm.
  • the outer diameter of the artificial tubular tissue depends on the type of tubular tissue to be produced, but is appropriately set according to the size of the inner diameter, and is not particularly limited, but is preferably 0.3 mm to 35 mm, preferably 0.7 mm to 25 mm. More preferably, 1.2 mm to 12 mm is further preferable.
  • the thickness of the artificial tubular structure is appropriately set depending on the relationship between the inner diameter and the outer shape, and is not particularly limited, but is preferably 0.1 mm to 3 mm, more preferably 0.3 mm to 2 mm, still more preferably 0.5 mm to 1 mm. ..
  • the pseudo-lesion portion may have a structure in which a bowl-shaped protruding portion is formed inward of the tube so as to narrow or occlude the lumen 4 of the artificial tubular tissue 2 (pseudo-lesion portion in FIG. 1). (Refer to 3A), it may be formed in a tubular shape inward of the artificial tubular tissue 2, and a pot-shaped inclined surface 5 that narrows inward is formed at the end of the opening of the pseudo-lesion portion. It may be formed (see pseudo-lesion 3B in FIG. 2).
  • the inner diameter is not particularly limited depending on the type of tubular tissue to be produced, but is preferably 0.1 mm to 3 mm, more preferably 0.2 mm to 2 mm, and more preferably 0.3 mm. ⁇ 1 mm is more preferable.
  • the outer diameter of the pseudo-lesion portion 3B depends on the type of tubular tissue to be produced, but is appropriately set according to the size of the inner diameter of the pseudo-lesion portion 3B, and is not particularly limited, but is preferably 0.2 mm to 32 mm. 0.6 mm to 22 mm is more preferable, and 1.1 mm to 12 mm is further preferable.
  • the thickness of the layer of the pseudo-lesion portion 3B is appropriately set according to the relationship between the inner diameter and the outer diameter, and by actually setting the thickness suitable for the degree of stenosis of the stenotic site, the thickness is such that suitable training can be reliably performed. As a result, through-hole training can be performed reliably, and the skill of the operator can be accurately improved.
  • the outer diameter of the pseudo-lesion portion 3B is formed larger than the inner diameter of the artificial tubular tissue.
  • the pseudo-lesion portion 3B is arranged in a compressed state in the artificial tubular tissue and is fixed in the artificial tubular tissue. Therefore, for example, a stent expansion technique practice or a calcification part cutting technique The displacement of the pseudo-lesion portion 3B during practice is suppressed. It may be fixed by using an adhesive, heat fusion or the like.
  • the method for producing the pseudo-lesion portion is not particularly limited, and the pseudo-lesion portion can be produced by a known molding method.
  • various molding methods can be used according to the target tubular structure model, such as extrusion molding, casting molding, injection molding, and vacuum forming.
  • melt flow rate is a value at a temperature of 230 ° C. and a load of 2.16 kg.
  • material ⁇ Hydrogenated block copolymer> "Septon 4055” manufactured by Kuraray Co., Ltd.
  • the hydrogenated block copolymer (A) and the inorganic filler (B) have the composition shown in Table 1, using a lavender plastic coder (PL2000 type manufactured by Brabender), 200 to 230 ° C., and a rotation speed of 50.
  • the resin composition was obtained by kneading at times / minute for 6 minutes.
  • the hydrogenated block copolymer (A) was supplied by the manufacturer as an amorphous powder.
  • the hydrogenated block copolymer (A), the inorganic filler (B), and the oil (C) have the composition shown in Table 1 and are used from 200 to 200 using a lavender plastic coder (PL2000 type manufactured by Brabender). A resin composition was obtained by kneading at 230 ° C. at a rotation speed of 50 times / minute for 6 minutes.
  • the hydrogenated block copolymer (A) was supplied by the manufacturer as an amorphous powder. A few days before kneading, a predetermined amount of oil (C) was added dropwise to the hydrogenated block copolymer (A) so that it was sufficiently impregnated. The amount of the oil (C) soaked here is included in the above-mentioned blending amount.
  • Comparative Example 3-5 A resin composition was obtained in the same manner as in Example 1 except that the following resin was used instead of the hydrogenated block copolymer (A).
  • Comparative Example 1 Polyethylene (PE), "Sumikasen C215" manufactured by Sumitomo Chemical Co., Ltd.
  • Comparative Example 2 Acrylonitrile-butadiene-styrene copolymer synthetic resin (ABS), "GR-2000” manufactured by Denka Corporation
  • Comparative Example 3 Polycarbonate (PC), "Iupilon ML200” manufactured by (Mitsubishi Engineering Plastics)
  • the lesion tubular tissue model of the example has physical properties similar to those of the lesion portion of the tubular tissue of animals including humans, and is a training model for palpation of the calcified part and a catheter procedure. It was clarified that it is useful as a training model for practice, a training model for practicing stent expansion technique, and a training model for practicing calcification cutting technique. On the other hand, the lesion tubular tissue model of the comparative example did not have physical properties similar to the lesion portion of the tubular tissue of animals including humans, or was not suitable as the training model.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pure & Applied Mathematics (AREA)
  • Educational Administration (AREA)
  • Computational Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Mathematical Analysis (AREA)
  • Mathematical Optimization (AREA)
  • Algebra (AREA)
  • Mathematical Physics (AREA)
  • Business, Economics & Management (AREA)
  • Medical Informatics (AREA)
  • Educational Technology (AREA)
  • Theoretical Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Instructional Devices (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne une composition de résine qui peut être utilisée pour un modèle de tissu tubulaire de lésion ayant des propriétés physiques similaires à celles d'une partie de lésion de tissu tubulaire d'un animal ou d'un être humain.　Ladite composition de résine contient : 100 parties en masse d'un copolymère séquencé hydrogéné en tant que composant (A) ; et 100-5900 parties en masse d'une charge inorganique en tant que composant (B).　
PCT/JP2020/023545 2019-06-27 2020-06-16 Composition de résine et modèle de tissu tubulaire de lésion Ceased WO2020262104A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE112020003114.4T DE112020003114T5 (de) 2019-06-27 2020-06-16 Harzzusammensetzung und modell für läsionierte tubuläre gewebe
JP2021528254A JP7482867B2 (ja) 2019-06-27 2020-06-16 樹脂組成物及び病変管状組織モデル

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019119481 2019-06-27
JP2019-119481 2019-06-27

Publications (1)

Publication Number Publication Date
WO2020262104A1 true WO2020262104A1 (fr) 2020-12-30

Family

ID=74060098

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/023545 Ceased WO2020262104A1 (fr) 2019-06-27 2020-06-16 Composition de résine et modèle de tissu tubulaire de lésion

Country Status (3)

Country Link
JP (1) JP7482867B2 (fr)
DE (1) DE112020003114T5 (fr)
WO (1) WO2020262104A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006206715A (ja) * 2005-01-27 2006-08-10 Dow Corning Toray Co Ltd 車両モールディング用熱可塑性エラストマー組成物および車両用モールディング付きガラス板
WO2017030145A1 (fr) * 2015-08-19 2017-02-23 デンカ株式会社 Composition de résine pour modèles d'organes
WO2018097311A1 (fr) * 2016-11-28 2018-05-31 クラレトレーディング株式会社 Résine composée, et mannequin
WO2018117212A1 (fr) * 2016-12-21 2018-06-28 デンカ株式会社 Composition de résine
WO2018151320A1 (fr) * 2017-02-20 2018-08-23 デンカ株式会社 Composition de résine et modèle biologique
JP2019065080A (ja) * 2017-09-28 2019-04-25 デンカ株式会社 導電性樹脂組成物およびそれを用いた手技練習用モデル
WO2020045552A1 (fr) * 2018-08-30 2020-03-05 デンカ株式会社 Composition de résine électroconductrice et article moulé constitué de celle-ci

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6372049B2 (ja) 2013-03-25 2018-08-15 株式会社マルイ 人工血管および人工血管の成形方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006206715A (ja) * 2005-01-27 2006-08-10 Dow Corning Toray Co Ltd 車両モールディング用熱可塑性エラストマー組成物および車両用モールディング付きガラス板
WO2017030145A1 (fr) * 2015-08-19 2017-02-23 デンカ株式会社 Composition de résine pour modèles d'organes
WO2018097311A1 (fr) * 2016-11-28 2018-05-31 クラレトレーディング株式会社 Résine composée, et mannequin
WO2018117212A1 (fr) * 2016-12-21 2018-06-28 デンカ株式会社 Composition de résine
WO2018151320A1 (fr) * 2017-02-20 2018-08-23 デンカ株式会社 Composition de résine et modèle biologique
JP2019065080A (ja) * 2017-09-28 2019-04-25 デンカ株式会社 導電性樹脂組成物およびそれを用いた手技練習用モデル
WO2020045552A1 (fr) * 2018-08-30 2020-03-05 デンカ株式会社 Composition de résine électroconductrice et article moulé constitué de celle-ci

Also Published As

Publication number Publication date
JP7482867B2 (ja) 2024-05-14
DE112020003114T5 (de) 2022-05-19
JPWO2020262104A1 (fr) 2020-12-30

Similar Documents

Publication Publication Date Title
JP6707547B2 (ja) 臓器モデル用樹脂組成物
JP7065173B2 (ja) コンパウンド樹脂及び人体模型
JP7340539B2 (ja) 樹脂組成物及びそれを用いた生体モデル
JP6913735B2 (ja) 樹脂組成物および生体モデル
JP7008033B2 (ja) 樹脂組成物
JP7366055B2 (ja) 人工血管
JP7482867B2 (ja) 樹脂組成物及び病変管状組織モデル
JP6948207B2 (ja) 導電性樹脂組成物およびそれを用いた手技練習用モデル

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20831570

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021528254

Country of ref document: JP

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 20831570

Country of ref document: EP

Kind code of ref document: A1